The United Kingdom and the United States have agreed to a important bilateral deal that will keep zero levies on British drug exports being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the National Health Service (NHS). This move secures that tariffs on these key goods will be held at nothing for a duration of 36 months.
This agreement is in response to earlier warnings to hike import taxes on branded pharmaceutical imports, with potential rates floated up to one hundred percent.
"This deal with the UK bolsters the international landscape for innovative medicines and introduces long-overdue equity to American-British drug exports," an announcement noted.
Trade Impact
Medicines constitute one of the UK's biggest export categories to the United States, which is easily the largest market for large companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This amount represented a significant portion of total UK exports in that timeframe.
"This agreement secures jobs, stimulates funding and facilitates the UK to establish itself as a international leader for life sciences," a government official remarked.
Key UK Commitments
The agreement involves several key changes from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments exceeded 20%.
Recent Tensions
The deal follows a ongoing row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were heightened by arguments that US customers were paying several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a share of its total funding over the last ten years.
